Skip to main content

Advertisement

Table 2 Outcomes of study patients after EECP treatment

From: Effect of enhanced external counterpulsation treatment on renal function in cardiac patients

Characteristics Median (IQR)
Baseline End of 35thsession Follow-up
(n = 30) (n = 27) (n = 30)
Systolic blood pressure (mm Hg) 122 120 130
  (113–133) (110–130) (120–130)
p-value   0.139a 0.473b
Diastolic blood pressure (mm Hg) 75 70 78
  (70–77) (70–80) (70–80)
p-value   0.839a 0.431b
Heart rate (beats/min) 70 68 71
  (61–75) (59–80) (63–80)
p-value   0.628a 0.071b
Creatinine (mg/dL) 1.02 0.97 1.01
  (0.84-1.36) (0.8-1.34) (0.85-1.36)
p-value   0.115a 0.156b
GFR (mL/min per 1.73 m2) 70.47 83.46 76.27
  (43.88-89.41) (47.26-97.51) (49.02-91.46)
p-value   0.075a 0.006b**
Cystatin C (mg/L) 1.00 0.91 0.94
  (0.78-1.31) (0.77-1.39) (0.77-1.27)
p-value   0.421a <0.001b**
NT-proBNP (pg/mL) 244 200 210
  (120–1067) (70–653) (123–398)
p-value   0.416a 0.425b
  1. aEnd of 35th session versus baseline, calculated using Wilcoxon signed ranks test.
  2. bFollow-up versus baseline, calculated using Wilcoxon signed ranks test.
  3. (**)indicated statistically significant p-value less than 0.01.